Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients

doi:10.3748/wjg.v28.i45.6380

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 45

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4624)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

275

WORD

HTML

2399

Figures (1-1)

365

Tables (1-7)

369

Sum=3482

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

377

Download

766

Sum=1143

Dec 7, 2022 (publication date) through Feb 3, 2025

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Dec 7, 2022; 28(45): 6380-6396
Published online Dec 7, 2022. doi: 10.3748/wjg.v28.i45.6380

Table 3 Treatment characteristics of genotype 1b-infected patients treated with direct-acting antiviral

Parameter	GT1b patients, n = 11385
History of previous therapy
Treatment-naïve	8497 (74.6)
Non-responder	949 (8.3)
Relapser	831 (7.3)
Discontinuation due to safety reason	338 (3)
Unknown type of response	728 (6.4)
No data	42 (0.4)
Previous treatment regimen in treatment-experienced, n = 2846
IFN ± RBV	149 (5.2)
PegIFN ± RBV	2080 (73.1)
IFN + RBV + DAA	438 (15.4)
DAA	155 (5.4)
No data	24 (0.9)
Genotype-specific treatment regimens
ASV + DCV	135 (1.2)
LDV/SOF ± RBV	2652 (23.3)
OBV/PTV/r + DSV ± RBV	3685 (32.4)
GZR/EBR ± RBV	2270 (19.9)
Other (SOF ± SMV ± DCV ± RBV, SMV ± DCV ± RBV)	16 (0.1)
Pangenotypic regimens
GLE/PIB	1684 (14.8)
GLE/PIB + SOF + RBV	3 (< 0.1)
SOF/VEL ± RBV	931 (8.2)
VOX/VEL/SOF	9 (0.1)

ASV: Asunaprevir; DAA: Direct-acting antiviral; DCV: Daclatasvir; DSV: Dasabuvir; EBR: Elbasvir; GLE: Glecaprevir; GT: Genotype; GZR: Grazoprevir; IFN: Interferon; LDV: Ledipasvir; OBV: Ombitasvir; PegIFN: Pegylated interferon; PIB: Pibrentasvir; PTV/r: Paritaprevir; RBV: Ribavirin; SMV: Simeprevir; SOF: Sofosbuvir; VEL: Velpatasvir; VOX: Voxilaprevir.

Citation: Zarębska-Michaluk D, Brzdęk M, Jaroszewicz J, Tudrujek-Zdunek M, Lorenc B, Klapaczyński J, Mazur W, Kazek A, Sitko M, Berak H, Janocha-Litwin J, Dybowska D, Supronowicz Ł, Krygier R, Citko J, Piekarska A, Flisiak R. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients. World J Gastroenterol 2022; 28(45): 6380-6396
URL: https://www.wjgnet.com/1007-9327/full/v28/i45/6380.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i45.6380